Scarica l'app Stockscreener
0.9023
6.45%
-0.0622
Dopo l'orario di chiusura:
.90
-0.0023
-0.25%
Precedente Chiudi:
$0.9645
Aprire:
$0.9451
Volume 24 ore:
1.29M
Relative Volume:
0.64
Capitalizzazione di mercato:
$88.41M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-8.86%
1M Prestazione:
+11.30%
6M Prestazione:
-83.92%
1 anno Prestazione:
-71.36%
Intervallo 1D:
$0.89
$0.9644
Intervallo di 1 settimana:
$0.8547
$1.01
Portata 52W:
$0.64
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Nome
Atyr Pharma Inc
Settore
Industria
Telefono
(858) 731-8389
Indirizzo
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.9023 | 94.51M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | Iniziato | Leerink Partners | Outperform |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Iniziato | Wells Fargo | Overweight |
| 2024-09-05 | Iniziato | Jefferies | Buy |
| 2023-07-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-10 | Iniziato | Laidlaw | Buy |
| 2020-08-17 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Iniziato | ROTH Capital | Buy |
| 2020-03-02 | Iniziato | Oppenheimer | Outperform |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2016-12-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Iniziato | Citigroup | Neutral |
| 2015-06-01 | Iniziato | Citigroup | Buy |
| 2015-06-01 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
aTyr Pharma (NASDAQ:ATYR) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
aTyr (ATYR) Achieves Milestone with Phase 3 Study Results - GuruFocus
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update - The Manila Times
ATYR Financials: Income Statement, Balance Sheet & Cash Flow | Atyr Pharma Inc - Stock Titan
ATYR PE Ratio & Valuation, Is ATYR Overvalued - Intellectia AI
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
aTyr Pharma Faces Pivotal Regulatory and Financial Milestones - AD HOC NEWS
aTyr Pharma (ATYR) Stock Analysis: Exploring a Potential 327% Upside in the Biotech Sector - DirectorsTalk Interviews
aTyr Pharma Q4 2025 Earnings Call Transcript - MarketBeat
aTyr Pharma (NASDAQ:ATYR) Trading Down 2.1%Should You Sell? - MarketBeat
ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
aTyr Pharma, Inc. (ATYR) Stock Analysis: Unveiling a Potential 338% Upside in the Biotechnology Arena - DirectorsTalk Interviews
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference - Bitget
aTyr Pharma Insiders Added US$926.8k Of Stock To Their Holdings - simplywall.st
ATyr Pharma to Present at the Leerink Partners Global Healthcare Conference - marketscreener.com
Sentiment Recap: Does aTyr Pharma Inc stock benefit from AI growth2025 Volatility Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Levels Update: Will CompoSecure Inc Equity Warrant stock go up in YEARVolume Spike & Low Volatility Stock Recommendations - baoquankhu1.vn
The Truth About aTyr Pharma Inc (LIFE): Tiny Stock, Huge Bets – But Is It Worth the Hype? - AD HOC NEWS
Is aTyr Pharma Inc. stock cheap compared to fundamentalsQuarterly Risk Review & Verified Swing Trading Watchlist - mfd.ru
Is aTyr Pharma Inc. backed by strong institutional buyingWeekly Trend Report & Smart Investment Allocation Tips - mfd.ru
Why hedge funds are buying aTyr Pharma Inc. stock2025 EndofYear Setup & Risk Managed Investment Entry Signals - mfd.ru
Why analysts upgrade aTyr Pharma Inc. stockJuly 2025 Fed Impact & Capital Protection Trade Alerts - mfd.ru
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: High-Growth - openPR.com
Is aTyr Pharma Inc. stock resilient to inflationJuly 2025 Market Mood & High Accuracy Trade Alerts - mfd.ru
Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected - RTTNews
Aug Summary: Does aTyr Pharma Inc have pricing powerJuly 2025 Reactions & Community Consensus Trade Signals - baoquankhu1.vn
Market Outlook: Does aTyr Pharma Inc have pricing powerJuly 2025 Pullbacks & High Conviction Investment Ideas - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: aTyr Pharma (ATYR), Pfizer (PFE) and Bicycle Therapeutics (BCYC) - The Globe and Mail
Atyr Pharma CEO Shukla sells $3.6k in stock - Investing.com
Atyr Pharma CEO Shukla sells $3.6k in stock By Investing.com - Investing.com Nigeria
Atyr Pharma CFO Broadfoot sells $1.5k in stock By Investing.com - Investing.com South Africa
Atyr Pharma CFO Broadfoot sells $1.5k in stock - Investing.com
aTyr Pharma general counsel sells $1091 in stock By Investing.com - Investing.com UK
aTyr Pharma general counsel sells $1091 in stock - Investing.com
FDA to review aTyr Pharma’s efzofitimod data in mid-April meeting - Investing.com Nigeria
aTyr Pharma gets FDA meeting on lead drug (ATYR:NASDAQ) - Seeking Alpha
Atyr Pharma announces scheduling of FDA type C meeting to discuss efzofitimod program in pulmonary sarcoidosis - marketscreener.com
aTyr Pharma (ATYR) Prepares for Key FDA Meeting on Efzofitimod - GuruFocus
aTyr Pharma Schedules FDA Meeting to Discuss Phase 3 EFZO-FIT™ Study Results for Efzofitimod in Pulmonary Sarcoidosis - Quiver Quantitative
ATyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis - marketscreener.com
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis - GlobeNewswire
FDA sets April meeting on lung sarcoidosis drug efzofitimod trial - Stock Titan
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Federated Hermes Inc. Sells 4,122,163 Shares of aTyr Pharma, Inc. $ATYR - MarketBeat
Short Interest in aTyr Pharma, Inc. (NASDAQ:ATYR) Drops By 14.7% - MarketBeat
Atyr Pharma Inc Azioni (ATYR) Dati Finanziari
Non sono disponibili dati finanziari per Atyr Pharma Inc (ATYR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Atyr Pharma Inc Azioni (ATYR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '26 |
Sale |
0.98 |
1,558 |
1,521 |
37,296 |
| DENYES NANCY | General Counsel |
Feb 04 '26 |
Sale |
0.98 |
1,118 |
1,091 |
33,124 |
| SCHIMMEL PAUL | Director |
Oct 08 '25 |
Buy |
0.90 |
682,001 |
612,437 |
1,095,024 |
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
| Gross Jane A | Director |
Mar 17 '25 |
Buy |
4.00 |
3,750 |
15,000 |
9,750 |
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):